Danaher Corp
DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3025% above fair value
$232.23−4.75 (-2.00%)
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Contribution / Headwind from Cepheid Respiratory by Year
Contribution / Headwind from Cepheid Respiratory Testing to Total Company Core Sales Growth (%)
Danaher Contribution / Headwind from Cepheid Respiratory: 0.5% in FY2025.
Latest, FY2025
0.5%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Danaher IR — nongaap_2026Q3
Where the FY2025 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Reported in Danaher Non-GAAP Reconciliations & Supplemental Data (8-K / IR PDF).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contribution / Headwind from Cepheid Respiratory Testing to Total Company Core Sales Growth (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.5% | – | Danaher IR — nongaap_2026Q3 ↗ |
Cite this data
StockData. (2026). Danaher Contribution / Headwind from Cepheid Respiratory (%), annual FY2025–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/resp-sales-headwind-total
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.